Evidence map›Paper›PMID 29755659›Full record

ArticleOncotarget2018

The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors.

Eduardo C A Silva, Flavio M Cárcano, Murilo Bonatelli, Maurício G Zaia, Filipa Morais-Santos, Fátima Baltazar, Luiz F Lopes, Cristovam Scapulatempo-Neto, Céline Pinheiro

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Exploring monocarboxylate transporter inhibition for cancer treatment.Exploration of targeted anti-tumor therapy · 2024
    Review
  6. Review
  7. Article
  8. Monocarboxylate transporters in cancer.Molecular metabolism · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Eduardo C A SilvaPathology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Flavio M CárcanoMedical Oncology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Murilo BonatelliMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Maurício G ZaiaMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Filipa Morais-SantosLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
Fátima BaltazarLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
Luiz F LopesBarretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.
Cristovam Scapulatempo-NetoPathology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Céline PinheiroBarretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.
Hospital de Câncer de Barretos · BRUniversity of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic reprogramming is one of the hallmarks of cancer. The hyperglycolytic phenotype is often associated with the overexpression of metabolism-associated proteins, such as monocarboxylate transporters (MCTs). MCTs are little explored in germ cell tumors (GCTs), thus, the opportunity to understand the relevance of these metabolic markers and their chaperone CD147 in this type of tumor arises. The main aim of this study was to evaluate the expression of MCT1, MCT2, MCT4 and CD147 in testicular GCT samples and the clinicopathological significance of these metabolism related proteins.

resultsMCT1, MCT4 and CD147 were associated with higher stages, higher M and N stages and histological type, while MCT4 was also associated with higher risk stratification, presence of vascular invasion, and lower overall and event free survival. MCT4 silencing in JEG-3 had no significant effect in cell viability, proliferation and death, as well as extracellular levels of glucose and lactate. However, MCT4-silenced cells showed an increase in migration and invasion.

conclusionThe proteins herein studied, with the exception of MCT2, were associated with characteristics of worse prognosis, lower global and event free survival of patients with GCTs. Also, MATERIALS AND

methodsImmunohistochemical expression was evaluated on samples from 149 adult patients with testicular GCT, arranged in Tissue Microarrays (TMAs), and associated with the clinicopathological data. Also, MCT4 silencing studies using siRNA were performed in JEG-3 cells.

Indexed as

immunohistochemistrymonocarboxylate transportertesticular germ cell tumorstesticular neoplasmsWarburg effect

Identifiers

PMID29755659
PMCPMC5945514
OpenAlexW2801631338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.